| Authors: |
Silva-Cayetano A; Immunology Program, Babraham Institute, Cambridge, UK., Fra-Bido S; Immunology Program, Babraham Institute, Cambridge, UK., Robert PA; Department of Systems Immunology and Braunschweig Integrated Centre of Systems Biology, Helmholtz Centre for Infection Research, Braunschweig, Germany.; Translational Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland., Innocentin S; Immunology Program, Babraham Institute, Cambridge, UK., Burton AR; Immunology Program, Babraham Institute, Cambridge, UK., Watson EM; Immunology Program, Babraham Institute, Cambridge, UK., Lee JL; Immunology Program, Babraham Institute, Cambridge, UK., Webb LMC; Immunology Program, Babraham Institute, Cambridge, UK., Foster WS; Immunology Program, Babraham Institute, Cambridge, UK., McKenzie RCJ; Immunology Program, Babraham Institute, Cambridge, UK., Bignon A; Immunology Program, Babraham Institute, Cambridge, UK., Vanderleyden I; Immunology Program, Babraham Institute, Cambridge, UK., Alterauge D; Institute for Immunology, Faculty of Medicine, Biomedical Center, LMU Munich, Munich, Germany., Lemos JP; Université Paris Cité, Institut de Recherche Saint Louis, EMiLy, INSERM U1160, Paris, France.; OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.; Sorbonne Université, INSERM, Institut de Myologie, Centre de Recherche en Myologie, Paris, France., Carr EJ; Immunology Program, Babraham Institute, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; The Francis Crick Institute, London, UK., Hill DL; Immunology Program, Babraham Institute, Cambridge, UK.; Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia., Cinti I; Department of Immunology and Inflammation, Imperial College London, London, UK., Balabanian K; Université Paris Cité, Institut de Recherche Saint Louis, EMiLy, INSERM U1160, Paris, France.; OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France., Baumjohann D; Institute for Immunology, Faculty of Medicine, Biomedical Center, LMU Munich, Munich, Germany.; Medical Clinic III for Oncology, Hematology, Immuno-Oncology and Rheumatology, University Hospital Bonn, University of Bonn, Bonn, Germany., Espeli M; Université Paris Cité, Institut de Recherche Saint Louis, EMiLy, INSERM U1160, Paris, France.; OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France., Meyer-Hermann M; Department of Systems Immunology and Braunschweig Integrated Centre of Systems Biology, Helmholtz Centre for Infection Research, Braunschweig, Germany.; Institute for Biochemistry, Biotechnology and Bioinformatics, Technische Universität Braunschweig, Braunschweig, Germany., Denton AE; Department of Immunology and Inflammation, Imperial College London, London, UK., Linterman MA; Immunology Program, Babraham Institute, Cambridge, UK. michelle.linterman@babraham.ac.uk. |
